Table 1.
JAK inhibitors for the topical treatment of AD.
| Name | Selectivity | Phase | Age/Severity | Regimens |
|---|---|---|---|---|
| Delgocitinib | pan-JAK | approved (Japan) | approved for children 2–15, adults >16, moderate-to-severe | 0.25% children 0.5% adults, b.i.d |
| Ruxolitinib | JAK1, 2 | approved (USA) | approved for >12, on trial for 2–12, mild-to-moderate | 1.5% b.i.d |
| Tofacitinib | JAK1, 3 | II | 18–60, mild-to-moderate | 2% b.i.d for 4 weeks |
| Brepocitinib | JAK1, TYK2 | II | 12–75, mild-to-moderate | 0.1%, 0.3%, 1%, 3% q.d, 0.3%, 1% b.i.d for 6 weeks |
| ATI-1777 | JAK1, 3 | II | 18–65, moderate-to-severe | 2% b.i.d for 4 weeks |
| Ifidancitinib | JAK1, 3 | II | >18, moderate-to-severe | 0.46% b.i.d for 4 weeks |
| Jaktinib | pan-JAK | II | 18–65, mild-to-moderate | 0.5%, 1.5%, 2.5% b.i.d, 2.5% q.d |
| Ivarmacitinib | JAK1 | III | >12, mild-to-moderate | 0.5%, 1%, 2% b.i.d |